Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

ARNA 4.04 +0.14 (3.59%)
price chart
The Future Is Bright For Arena Pharmaceuticals
Clearly, Belviq gives Arena the chance to become a legitimate pharmaceutical company that deserves consideration as an investment, not just a fleeting trade.
Related articles »  
A Realistic View Of Belviq In The Short Term
Over my 10-year career trading biotechs, I have found that retail investors are all too often unrealistic about new therapies and the subsequent appreciation of a company's common stock. The retail crowd surrounding ARNA appears to be repeating this ...
Related articles »  
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Related articles »  
Vivus Or Arena: Who Has The Edge?
Two of the three major players in the treatment of obesity, VIVUS Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) released their financial results and provided an update on recent developments.
Vivus Weight-Loss Drug Launch In Early Trouble
Vivus 'fesses up to another setback for Qsymia sales  FiercePharma
Related articles »  
CEO of the Year, Final Round: Arena Pharmaceuticals vs. Lumber Liquidators
On one hand we have Jack Lief of Arena Pharmaceuticals, who led his company to develop Belviq, the anti-obesity drug recently approved by the FDA that's currently in the driver's seat to be the first fat-busting drug approved internationally (all ...
Arena Pharma Is Still A Good Short
My advice to lorcaserin bulls would be to cherish the moment but sell the stock...This is as good as it gets. If you're one of the lucky few that can find shares to borrow, congrats -- you've got a good short.
Related articles »  
Arena Pharma Sinks Under Weight Of Vivus' Troubles
SAN DIEGO ( TheStreet) -- Jefferies analyst Thomas Wei is still an Arena Pharmaceuticals (ARNA) bull, just not as much after slashing his sales forecast for the yet-to-be-launched obesity pill Belviq.
Related articles »  
Theravance: Still A Buy On Weakness
More recently, over the last month, negativity in the markets was acute: the S&P is down 2.5%, while the pharmaceutical ETF is down even more, declining 7%. Arena Pharmaceuticals (NASDAQ:ARNA), VVUS Inc. (NASDAQ:VVUS), and Theravance Inc.
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Arena moved up 3% to $9.19. Orexigen jumped 7% to $4.67. Orexigen is developing a drug, contrave, which is being tested for safety.
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Vivus Rallies After Aetna Drug Policy Change  Seeking Alpha
Related articles »  
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the October 15 and October 31 settlement dates.
Related articles »